Despite great advances in treatment of many forms of malignancy, glioblastoma multiforme (GBM), the most common type of primary brain tumor, remains a vexing clinical problem with a median survival of 12–15 months and only anecdotal long-term survivors. A great deal of work has been done in an effort to understand the biology and genetics of GBM, but clinically significant advances in therapy have remained elusive. Therapy for GBM is hindered by central nervous system (CNS) and systemic toxicities, impaired delivery of therapeutic agents into the CNS due to the blood-brain barrier, tumor heterogeneity, and an incomplete understanding of the underlying biology of the disease. Furthermore, there is a great difficulty in assessing therapeutic response with current imaging techniques.

We are particularly interested in manuscripts which advance the leading edge of current technology in the biology, therapeutics, and imaging of GBM. Basic, translational, and clinical investigations into the application of novel techniques are encouraged as are thorough reviews of current topics in GBM. Potential topics include, but are not limited to:

• Molecular and biological research in GBM
• Stem cells in GBM, including implications for therapy
• Neurocognitive measures and outcomes for patients with GBM
• Advances in imaging of GBM
• Novel therapies for GBM
• Therapy for recurrent/progressive GBM
• Clinical trial results for GBM

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/nri/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable: